By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Endocrine therapy is the mainstay of the management of hormone receptor (HR) positive breast cancer. Until now, fulvestrant remained the only selective
By Dr. Harsh Parmar Hackensack Meridian Health In an unplanned interim analysis of an international phase-III trial (ATLAS) by Dytfeld et al., performed across 12 centers in Poland and the US,
More
By Dr. Abhishek A. Mangaonkar Mayo Clinic The phase 2 FIGHT-203 trial (NCT#03011372) studied 28 patients with relapsed/refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. FGFR1 rearrangement should be suspected in patients who
More
Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Philadelphia positive acute lymphoblastic leukemia treatment has been driven by the combination of tyrosine kinase inhibitors targeting BCR-ABL in conjunction with
More
Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic In the phase III AGILE trial reported in the New England Journal of Medicine, Pau
More
By Luke Fletcher, MD Willamette Valley Cancer Institute & Research Center Imetelstat, a telomerase inhibitor, has shown interesting promise for ESA refractory or unlikely to respond low-risk Myelodysplastic syndrome (MDS). In
More
By Paolo Tarantino, MD Dana-Farber Cancer Institute/Harvard Medical School “Overall, a major shift in the way we treat breast cancer has occurred in 2022, with the demonstration that patients with tumors
More
Local Oncologist Involved with the Binaytara Foundation Since 2019 Meet Dr. Fengting Yan, one of our wonderful Education Committee members! Dr. Yan is an oncologist who specializes in women’s cancer practicing at
More
In this blog article, Dr. Dan Milner, Chief Medical Officer of the American Society for Clinical Pathology, discusses his experience about his participation in the 2022 Summit on Cancer Health Disparities held
More